New crown vaccine sales revenue declined sharply year-on-year Conchino’s 2022 prep loss topped nearly 1 billion yuan
Read Time:1 Minute, 9 Second
Conxino released a performance forecast in the evening of January 30, expecting that the net profit attributable to owners of the parent company for the year 2022 will be a loss compared with the same period of the previous year, and the net profit attributable to owners of the parent company will be -830 million yuan to -996 million yuan.
For the reason of the loss, the company said that during the reporting period, the domestic and international new crown vaccine market environment has changed significantly, the demand for new crown vaccine has shown a significant decline compared with the same period last year, the growth rate of global new crown vaccination has slowed down, and some regions show the situation that the supply exceeds the demand, the market competition has been intensified, the company’s new crown vaccine product sales revenue has dropped significantly compared with the same period last year, while the commercialization process continues to make At the same time, the company’s net profit attributable to the owners of the parent company was loss due to the increase of sales expense compared with the same period last year and the impairment of the inventory related to New Crown vaccine, which showed signs of impairment.
As of today’s close, Kangxino was down 2.62% at 142.86 yuan, with a total market capitalization of 35.351 billion yuan.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
Average Rating